JP2009534292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534292A5 JP2009534292A5 JP2008544698A JP2008544698A JP2009534292A5 JP 2009534292 A5 JP2009534292 A5 JP 2009534292A5 JP 2008544698 A JP2008544698 A JP 2008544698A JP 2008544698 A JP2008544698 A JP 2008544698A JP 2009534292 A5 JP2009534292 A5 JP 2009534292A5
- Authority
- JP
- Japan
- Prior art keywords
- moisture
- measured
- results
- conditions
- stored
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
Description
試験例２
実施例３〜６で得られた錠剤、比較例３の混合造粒末２７０ｍｇを防湿包装し、４０℃７５％ＲＨの条件下１ヶ月間保存し、化合物Ａ由来の酸分解物のケトン体の増加量を測定した。結果を表１０に示す。
Test example 2
The tablets obtained in Examples 3 to 6 and 270 mg of the mixed granulated powder of Comparative Example 3 were moisture-proof packaged and stored for 1 month under the conditions of 40 ° C. and 75% RH. The increase was measured. The results are shown in Table 10.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79517906P | 2006-04-27 | 2006-04-27 | |
| PCT/JP2007/059428 WO2007126135A1 (en) | 2006-04-27 | 2007-04-26 | Pharmaceutical composition of angiotensin ii antagonists with pioglitazone hcl |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009534292A JP2009534292A (en) | 2009-09-24 |
| JP2009534292A5 true JP2009534292A5 (en) | 2010-04-30 |
Family
ID=38328300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008544698A Abandoned JP2009534292A (en) | 2006-04-27 | 2007-04-26 | Pharmaceutical composition of angiotensin II antagonist with pioglitazone hydrochloride |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2009534292A (en) |
| AR (1) | AR060663A1 (en) |
| CL (1) | CL2007001195A1 (en) |
| PE (1) | PE20080696A1 (en) |
| TW (1) | TW200800299A (en) |
| WO (1) | WO2007126135A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| WO2008140853A2 (en) * | 2007-05-08 | 2008-11-20 | Dow Global Technologies Inc. | Water dispersible polymer compositions |
| WO2013058409A1 (en) | 2011-10-21 | 2013-04-25 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW284688B (en) * | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
| WO2003013609A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
| CA2583768A1 (en) * | 2004-10-07 | 2006-04-13 | Takeda Pharmaceutical Company Limited | Agent for prophylaxis or treatment of metabolic syndrome |
-
2007
- 2007-04-26 PE PE2007000517A patent/PE20080696A1/en not_active Application Discontinuation
- 2007-04-26 TW TW096114770A patent/TW200800299A/en unknown
- 2007-04-26 JP JP2008544698A patent/JP2009534292A/en not_active Abandoned
- 2007-04-26 CL CL2007001195A patent/CL2007001195A1/en unknown
- 2007-04-26 AR ARP070101812A patent/AR060663A1/en unknown
- 2007-04-26 WO PCT/JP2007/059428 patent/WO2007126135A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012031147A5 (en) | ||
| SA112330957B1 (en) | Hemostatic compositions | |
| RU2582676C3 (en) | SOME CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS | |
| EA201190092A1 (en) | COMPOSITIONS WITH EXTENDED SHIPPING FOR ORAL APPLICATION CONTAINING AMORPHOUS BARDOXOLON METHYL (CDDO-ME) | |
| MX2010005087A (en) | Fast release solid formulation, preparation and use thereof. | |
| JP2010242999A5 (en) | ||
| IL212435A (en) | Isoindoline compounds, pharmaceutical compositions comprising the same and use thereof for the preparation of medicaments | |
| JP2012158592A5 (en) | ||
| TR201903195T4 (en) | Apixaban formulations. | |
| WO2009063222A3 (en) | Solid compositions | |
| IL233282A (en) | Crystalline forms of 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine monohydrochloride, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments | |
| EA201201050A1 (en) | PYRAZOLES AS AN ANTAGONISTS CRTH2 | |
| EP2121658A4 (en) | Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same | |
| MX2010003001A (en) | Quinoline derivatives as 5ht5a receptor antagonists. | |
| NZ734152A (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| IL206514A0 (en) | Triazole oxadiazoles derivatives, their preparation and pharmaceutical compositions containing them | |
| JP2009534292A5 (en) | ||
| JP2014024874A5 (en) | ||
| HU0900376D0 (en) | Nanoparticulate candesartan cilexetil composition, process for the preparation thereof and pharmaceutical compositions containing them | |
| WO2011141791A3 (en) | Extended release formulations of desvenlafaxine base | |
| UA116204C2 (en) | Prasugrel-containing immediate release stable oral pharmaceutical compositions | |
| EP2497464A3 (en) | Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture | |
| TR201007250A2 (en) | Formulation containing cellobiose. | |
| JP2012046484A5 (en) | ||
| EA201291189A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING SOLIPHENACIN, AND METHOD FOR ITS OBTAINING |